Current Therapeutic Research: 68(4)




Yüklə 14.96 Kb.
tarix30.04.2016
ölçüsü14.96 Kb.
مرفق1 : نموذج للملخصات البحثية إنجليزي


Title

Loss of smell (Anosmia) and taste (Ageusia) in a patient treated with pegylated interferon Alfa and Ribavirin










Author-s

Mayet, Ahmed Yacoob

Contact lnfo

iymayet@ksu.edu.sa Telephone   +966 1 4677487  +966 1 4679519  

Fax:  Address PO.Box: 2457      Riyadh: 11451  Kingdom Saudi Arabia



Department

Clinical Pharmacy

Major

Clinical Pharmacy

citation

Current Therapeutic Research: 68(4); 271-277

Year of Publication

2007

Publisher

Excerpta Medica

Sponsor

KSU

Type of Publication

Research

ISSN

0011-393X

URI/DOI

http://repository.ksu.edu.sa/jspui/bitstream/123456789/2481/1/Loss%20of%20smell%20%28Anosmia%29%20and%20taste%20%28Ageusia%29%20in%20a%20patient%20treated%20with%20pegylated%20interferon%20Alfa%20and%20Ribavirin.pdf

Full Text (Yes,No)

Yes

Key words

Anosmia pegylated interferon alfa-2a Ribavirin Hepatitis C virus

Abstract

Introduction: Anosmia, the loss of the sense of smell, is a rare adverse event associated with interferon alpha (INF-a). Millions of patients with hepatitis B and hepatitis C virus (HCV) infection are currently treated with INF-alfa-2a daily. Only 5 cases of anosmia have been reported in the literature, and none was associated with pegylated INF-alfa. Case summary: A 55-year-old Arab male (height, 5'1"; weight, 81 kg) with chronic HCV developed anosmia and ageusia (loss of the sense of taste) after 36 weeks of treatment for HCV with subcutaneous pegylated INF-alfa-2a 180 μg and ribavirin 1200 mg. Treatment was continued for 12 additional weeks before being discontinued. Twenty-four weeks after treatment was discontinued, HCV-RNA was undetectable and, during the same visit, the patient reported that he had regained his sense of smell a few weeks previously. The Naranjo algorithm score was 7, representing a probable association of anosmia with INF-alfa-2a treatment. Other etiologies for loss of smell and taste were ruled out. Conclusions: We report a case of anosmia and ageusia in a patient treated with pegylated INF-alfa-2b and ribavirin for HCV infection. The patient regained his sense of smell and taste within 24 weeks of stopping treatment.


Verilənlər bazası müəlliflik hüququ ilə müdafiə olunur ©www.azrefs.org 2016
rəhbərliyinə müraciət

    Ana səhifə